Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 947-618-5 | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
EGGE 2806-1 is not skin sensitising in a mouse LLNA (Leidenfrost, 2015).
Key value for chemical safety assessment
Skin sensitisation
Link to relevant study records
- Endpoint:
- skin sensitisation: in vivo (LLNA)
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 19 to 22 May 2015
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 429 (Skin Sensitisation: Local Lymph Node Assay)
- Deviations:
- yes
- Remarks:
- - modified LLNA (IMDS): Measurement of cell counts instead of radioactive labeling. In addition, measurements of ear swelling and ear weights were done to discriminate the irritating potential from the sensitizing potential of the test substance.
- Principles of method if other than guideline:
- Modified LLNA (IMDS; Integrated Model for the Differentiation of Skin Reactions). By comparing the specific immune reaction induced by the test item in the draining lymph nodes (cell counts / lymph node weights) with the immediate nonspecific acute skin reaction (ear swelling / ear weight), it is possible to differentiate the irritant potential from the sensitizing potential of the compound tested .Modifications are authorized in the OECD TG 429 and in the Note for Guidance SWP/2145/00 of the CPMP (2001). Detailed Information on validation of IMDS, scientific justification, method and assessment of results are given in:
- Homey, B., von Schilling, C., Blümel, J., Schuppe, H.-C., Ruzicka, T., Ahr, H.-J., Lehmann, P. and Vohr, H.-W.: An integrated Model for the Differentiation of Chemical-Induced Allergic and Irritant Skin Reactions (IMDS). Toxicol. and Appl. Pharmacol. 153, 83-94 (1998).
- Vohr, H.-W., Blümel, J., Blotz, A., Homey, B. and Ahr, H.J. An intra-laboratory validation of IMDS: Discrimination between (Photo) Allergic and (Photo) Irritant Skin Reactions in Mice. Arch. Toxicol., 73, 501-509 (2000).
- ECETOC Technical Report No. 87, Brussels (2003)
- Ehling G., Hecht M., Heusener A., Huesler J., Gamer A.O., v. Loveren H., Maurer Th., Riecke K., Ullmann L., Ulrich P., Vandebriel R., Vohr H.-W. An European Inter-Laboratory Validation of Alternative Endpoints of the Murine Local Lymph Node Assay. 2nd ROUND.Toxicology 212 (2005), 69-79
- Gamer A.O., Nies E., Vohr H.-W.: Local Lymph Node Assay (LLNA): Comparison of different protocols by testing skin-sensitizing epoxy resin system components. Reg. Tox. Pharmacol. 52 (2008), 290-298. - GLP compliance:
- yes (incl. QA statement)
- Type of study:
- mouse local lymph node assay (LLNA)
- Specific details on test material used for the study:
- - Solubility and stability of the test substance in the solvent/vehicle: The stability of the test item in the vehicle was analytically verified for up to 2 hours. The test item formulations in the vehicle were visually described as solutions.SOURCE OF TES
- Treatment of test material prior to testing:The test item was melted for approx. 3 hours in a hot cabinet (110°C) before weighing. The test item was formulated in DMF by mixing immediately before each application.
FORM AS APPLIED IN THE TEST (if different from that of starting material): The formulations were visually described as solutions. - Species:
- mouse
- Strain:
- other: HsdWin:NMRI
- Sex:
- female
- Details on test animals and environmental conditions:
- TEST ANIMALS
- Strain: HsdWin: NMRI (SPF-bred)
- Source: Harlan Nederland, 5960 AD Horst, The Netherlands
- Age at study initiation: 9 weeks
- Weight at study initiation: 28-36 g
- Housing: During the study period the animals were single-housed in Makrolon type II cages.
- Diet and water: ad libitum
- Acclimation period: at least 6 days
- Indication of any skin lesions: no
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 22 +/- 2
- Humidity (%): 40 -70
- Air changes (per hr): about 10
- Photoperiod (hrs dark / hrs light): 12 / 12 - Vehicle:
- dimethylformamide
- Concentration:
- 0 (vehicle control), 2, 10, 50 % (based on the experience with this test system and expected solubility of the test item)
- No. of animals per dose:
- six
- Details on study design:
- TREATMENT PREPARATION AND ADMINISTRATION:
The test item was formulated once before application in the vehicle. The formulation was applied epicutaneously onto the dorsal part of both ears of the animals. This treatment was repeated on three consecutive days (d1, d2 and d3). The volume administered was 25 µL/ear. The concentrations used were based on the experiences with the test system and the expected solubility of the test item. For negative control a dose group treated only with the vehicle in the above described manner was used.
The animals were anaesthetized by inhalation of carbon dioxide and sacrificed one day after the last application (d4). The appropriate organs were then removed. Lymphatic organs (the auricular lymph nodes) were transferred into phosphate buffered solution (PBS).
Investigations:
- weight of lymph nodes
- cell counts in lymph nodes
- stimulation index is calculated by dividing the absolute number of weight or cell counts of the substance treated lymph nodes by the vehicle treated ones.
- ear swelling
- ear weight
- body weights
- LLN weight and cell count determinations: The weight and cell count determinations were carried out by appropriate laboratory procedures. The weights of the lymph nodes were determined on a Mettler automatic balanceand manually recorded. LN cell suspensions were generated by crushing the lymph nodes through a sieve into 2 ml medium, the cell counts per ml were then determined using a Multisizer 3® from Coulter Electronics. These data were directly collected and processed by computer (Multisizer 3 software and Excel). Means, stimulation indices and standard deviations were calculated by an Excel data sheet. The so-called stimulation (or LLN-) index is calculated by dividing the absolute number of weight or cell counts of the substance treated lymph nodes by the vehicle treated ones. Thus, in case of no stimulating effect the index is about 1.00 (±relative standard deviation), and the indices of vehicle treated animals are set to 1.00 (±relative standard deviation).
The Local Lymph Node Assay Test methodology was checked for reliability in a test on female NMRI mice using alpha hexyl cinnamic aldehyde formulated in different vehicles (PEG 400, DAE 433, DMF, MEK, acetone/olive oil (4:1) and Cremophor ELl physiological saline solution 2% v/v) at concentrations of3 %, 10% and 30%. The sensitivity as well as the reliability of the experimental technique is thus confirmed bythis study.
A similar check is done in regular intervals using one of the above mentioned vehicles in order to confirm the reliability of the method. The last reliability test (March 2015) using alpha hexyl cinnamic aldehyde formulated in acetone/olive oil (4:1) at concentrations of2.5 %, 10% and 40% clearly confirmed the sensitizing potential of the test item. - Positive control substance(s):
- hexyl cinnamic aldehyde (CAS No 101-86-0)
- Statistics:
- When it was statistically reasonable, the values from treated groups were compared with those from the control groups (vehicle) by a one-way analysis of variance (ANOVA) when the
variances are considered homogeneous according to a homogeneity testing like Cochran's test. Alternatively, if the variances are considered to be heterogenous (p <= 0.05), a non-parametric Kruskal-Wallis test has been used (Kruskal-Wallis ANOVA) at significance
levels of 5 %. Two sided multiple test procedures were done according to Dunnett or Bonferroni-Holm (Mann-Whitney test included), respectively. In addition, for the LLNA/IMDS the smallest significant differences in the means were calculated by Scheffe's method, which can be used for both equal and unequal sample sizes. In this method of statistical processing of measurements a large number of comparisons are made, and as a result of the multiple tests the overall probability of error is considerably greater than the p values suggest (increased number offalse~positive results). On the other hand, the known methods of adjusting p values lead to an excessive increase in the number of false negatives. In view of these problems the biological and toxicological relevance is also taken into consideration in the evaluation of statistical significance. For this reason, in the case of indices only the standard deviations between groups and difference analysis of the mean values were used in the evaluation of the biological relevance Individual data were recorded and archived, but in some cases e.g. ear swelling and ear weight are not reported. - Positive control results:
- The sensitivity as well as the reliability of the experimental technique is confirmed by the studies with Alpha Hexyl Cinnamic Aldehyde (see details on study design).
- Parameter:
- SI
- Value:
- 0.94
- Test group / Remarks:
- high dose (50%)
- Remarks on result:
- other: cell count index of the high dose group (50%): "positiv" level of 1.4 (cut-off value for skin sensitisation) was not exceeded in any dose group
- Cellular proliferation data / Observations:
- BODY WEIGHTS: The body weights of the animals were not affected by any of the treatment.
- Interpretation of results:
- other: not sensitising
- Executive summary:
The test item was assessed for both its skin sensitizing and irritant potential in a modified Local Lymph Node Assay with the following concentrations: 0 % (vehicle control), 2 %, 10 % and 50 %. The test item was formulated in dimethylformamide (DMF). Compared to vehicle (DMF) treated animals there was no increase regarding the cell counts and the weights of the draining lymph nodes up to and including the highest dose group. Therefore there is no indication for a specific skin sensitizing effect after administration of a concentration of up to and including 50 % test item in this test system. The "positive level" of ear swelling which is 2 x 10-2mm increase, i.e. about 10 % of the control values, was not exceeded in any dose group. No substance specific effects were determined for ear weights either. Thus the study does not point to an irritant potential of the test item, too.The validity of the assay was demonstrated by the positive results with Alpha Hexyl Cinnamic Aldehyde which has been demonstrated in regular intervals in separate studies.
.
Reference
Table 1: Summary of the LLNA/IMDS results (means of 6 animals per group)
Parameter investigated | Vehicle control | Dose 2% | Dose 10% | Dose 50% |
Stimulation index: weight of draining lymph nodes | 1.00 | 0.87 | 0.89 | 1.08 |
Stimulation index: cell count in draining lymph nodes | 1.00 | 0.85 | 0.87 | 0.94 |
Ear swelling in 0.01 mm on day 4 (index) | 19.67 (1) | 19.00 (0.97) | 19.0 (0.97) | 19.5 (0.99) |
Ear weight in mg / 8 mm diameter punch on day 4 (index) | 14.39 (1) | 13.71 (0.95) | 13.98 (0.97) | 13.53 (0.94) |
Test item - sensitizing potential: The NMRI mice did not show an increase in stimulation indices for cell counts, which is of statistical significance, and for weights of the draining lymph nodes after application of the test item up to and including 50 %. In addition, the "positive level", which is 1.4 for cell count indices, was not exceeded in any dose group.
Test item - irritating potential: The "positive level" of ear swelling, indicating irritating potential, which is 2x10-2mm increase, i.e. about 10 % of the control values, was not exceeded in any dose group.
The validity of the assay was demonstrated by the positive results with Alpha Hexyl Cinnamic Aldehyde which has been demonstrated in regular intervals in separate studies.
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed (not sensitising)
- Additional information:
The test item was assessed for both its skin sensitizing and irritant potential in a modified Local Lymph Node Assay with the following concentrations: 0 % (vehicle control), 2 %, 10 % and 50 % (Leidenfrost, 2015). The test item was formulated in dimethylformamide (DMF). Compared to vehicle (DMF) treated animals there was no increase regarding the cell counts and the weights of the draining lymph nodes up to and including the highest dose group. Therefore there is no indication for a specific skin sensitizing effect after administration of a concentration of up to and including 50 % test item in this test system. The "positive level" of ear swelling which is 2 x 10-2mm increase, i.e. about 10 % of the control values, was not exceeded in any dose group. No substance specific effects were determined for ear weights either. Thus the study does not point to an irritant potential of the test item, too.The validity of the assay was demonstrated by the positive results with Alpha Hexyl Cinnamic Aldehyde which has been demonstrated in regular intervals in separate studies.
Respiratory sensitisation
Endpoint conclusion
- Endpoint conclusion:
- no study available
Justification for classification or non-classification
Based on the available study results a classification according to Regulation (EC) No. 1272/2008 (CLP) is not required.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.